SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders debating whether guidance, subscriber engagement and ad growth can offset concerns about slowing growth and the content slate. Sentiment leans bearish amid the stocks decline and traders claims of repeated post-earnings selloffs, though some see low expectations as room for a rebound.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp rebound and heavy buying have fueled attention as traders anticipate the 80th-event trigger and final-analysis results for SELLASs Phase 3 REGAL trial of GPS. Some also read the CEOs anniversary remarks and planned ASH presence as possible buyout signals, but others stress there is no confirmed deal or trial result and that the price move may be trading activity.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly earnings and forward guidance are the dominant focus, particularly whether AI and data-center revenue can justify heavy capital spending. Traders are split between expecting a profitable report and rally and worrying about debt, spending, valuation, and an upcoming share unlock.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets reported Willow quantum-computing advanceusing magic state cultivation to cut errors roughly 40-foldhas sparked interest, though traders question whether it will matter to the stock near term as the share price remains weak. Conversation also centers on the upcoming earnings report and whether the recent pullback is a buying opportunity or reflects broader tech and AI-spending concerns.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is drawing attention amid broader funding and return concerns for AI-focused neoclouds, with traders also questioning the companys execution, dilution and delayed Horizon capacity. Co-CEO Daniel Roberts comments that data-center construction has been cash-funded and customer prepayments help finance GPUs are cited by bulls, but have not eased the bearish debate or frustration that IREN is lagging peers.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs rise is being linked by traders both to strength across biotech and to the reported Silence Therapeutics acquisition, which some see as a sign of pharma interest in siRNA therapies relevant to Sareptas pipeline. Others view the move as a sector-driven bounce or short covering, and say upcoming DM1 and FSHD datanot a confirmed Sarepta-specific announcementwill be key.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas potential Monee fintech listing and launch of its Sea Cloud AI venture are fueling debate as shares sell off: some traders see a possible Monee separation and cloud investment as sources of uncertainty, while others argue the moves could unlock value and expand growth. The decline has intensified bearish technical commentary and speculation about insider selling, alongside bullish claims that the reaction is an overreaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM shares are falling despite a third-quarter earnings and revenue beat and a new buyback authorization, as investors focus on a narrowed full-year profit outlook with its midpoint unchanged rather than an upgrade. Traders are split between viewing the selloff as overdone given stronger cash-flow guidance and capital returns, and seeing the outlook and softer vehicle sales as reasons for caution.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is drawing attention as traders position around the detailed Phase 3 results for its personalized melanoma cancer vaccine with Merck at ESMO, following a positive topline readout. Bulls see the data as validation of its oncology platform, while skeptics warn that the sharp rally may have priced in strong results and could reverse on a sell-the-news reaction.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings are the main focus, with traders watching Google Cloud and Gemini for signs of growth. The discussion is divided between optimism about AI and cloud momentum and concern that heavy AI spending, alongside recent share-price weakness, could weigh on returns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.read more...

Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study

MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.

Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?

Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study

Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?

Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why You Should Add ARQT Stock to Your Portfolio Now

Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen 

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.


5 Biotech Stocks Worth Adding to Your Portfolio Now 

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector. 

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +22.22% and +6.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Viatris Gears Up to Report Q2 Earnings: What's in the Cards?

VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally

Equity

Bullish Sentiment

Arcutis Biotherapeutics Inc.'s stock jumped 8.7% in after-hours trading on Tuesday following a stronger-than-expected fourth-quarter performance, driven by surging demand for its flagship inflammatory dermatology treatment.&nbsp;The upbeat results ignited a sharp rise in retail investor engagement, with message volume on Stocktwits soaring nearly 430% and sentiment shifting from ‘neutral’ to ‘bullish’ within a day.<figure class="image"><img style="aspect-ratio:1266/724;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ARQT_message_volume_meter_as_of_Feb_25_2a89fcb8eb.png" alt="ARQT message volume meter as of Feb 25.png" width="1266" height="724"><figcaption>ARQT message volume meter as of Feb 25 | source: Stocktwits</figcaption></figure>The company reported a fourth-quarter loss per share of $0.09, significantly better than the anticipated loss of $0.26.&nbsp;Revenue hit $71.4 million, well above the consensus estimate of $60.52 million.&nbsp;Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.CEO Frank Watanabe attributed the company's strong momentum to a well-executed pricing and access strategy and the successful commercial launch of two new Zoryve indications in 2024.Retail investors reacted enthusiastically, with one user calling the earnings report a "10/10 release."&nbsp;<stembedurl>https://stocktwits.com/Dilly_Poppins/message/605742985</stembedurl>Another investor speculated that given Zoryve's rapid growth and multiple indications, Arcutis could become an attractive acquisition target for larger biopharma companies.<stembedurl>https://stocktwits.com/lyonsa14/message/605727827</stembedurl>Chief Commercial Officer L. Todd Edward said the company plans to introduce a new foam formulation of Zoryve for body and scalp psoriasis in the second half of the year. A pediatric label expansion is also in the pipeline.&nbsp;He highlighted strong Medicaid coverage and ongoing Medicare Part D negotiations as key factors that could help Arcutis deepen its market penetration.The company said it ended 2024 with $228.6 million in cash and marketable securities and has significantly reduced interest expenses after repaying $100 million in debt in October.&nbsp;Arcutis reaffirmed its target of reaching cash flow break-even in 2026.According to Koyfin data, short interest in the stock last stood at 16.2%, down from 19.7% at the beginning of the year. Despite the after-hours rally, Arcutis shares are down more than 14% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Current Price	$32.76
Prev Close	$31.89
Open	$31.88
Dividend Yield	0.00%
50-Day Moving Average	$25.61
Beta	1.30
Avg. Volume	3.43M
PE Ratio	153.98

52-Week High	$33.01
52-Week Low	$19.30
Market Capitalization	$4.01B
EPS (Annual)	-$0.1269
Price to Book	18.16
Revenue Per Employee	$1.06M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARQT Fundamentals